Tyra Biosciences Extends Cash Runway to 2H 2028, Reports Q1 Results & Clinical Progress

summarizeSummary

Tyra Biosciences reported Q1 2026 financial results, extending its cash runway into the second half of 2028 following a successful $147.9 million capital raise through its ATM program, alongside significant clinical trial advancements.

check_boxKey Events

• Extended Cash Runway

  The company reported cash, cash equivalents, and marketable securities of $383.5 million as of March 31, 2026, extending its financial runway into the second half of 2028, a significant improvement from the previous guidance of through at least 2027.

• Successful Capital Raise

  Tyra Biosciences generated $147.9 million in net proceeds during Q1 2026 by issuing and selling 4,690,532 shares of common stock through its 'at-the-market' offering program to a large investment management firm.

• Pivotal Trial Initiation

  The first patient has been dosed in SURF303, a Phase 2a/b multicenter, open-label study with pivotal intent, evaluating dabogratinib for low-grade upper tract urothelial carcinoma (LG-UTUC), with initial results expected in 2027.

• Upcoming Clinical Data Readouts

  Initial three-month complete response data from the SURF302 study (IR NMIBC) is expected in August 2026, and initial results from the BEACH301 safety sentinel cohort (achondroplasia) are anticipated in Q4 2026.

auto_awesomeAnalysis

This filing is highly important for Tyra Biosciences as it significantly extends the company's financial runway into the second half of 2028, providing crucial stability for its ongoing clinical programs. The successful utilization of its at-the-market (ATM) offering, raising $147.9 million, underpins this extended runway. Furthermore, the company reported key clinical advancements, including the dosing of the first patient in a pivotal Phase 2a/b study (SURF303) and upcoming data readouts for two other Phase 2 trials (SURF302 and BEACH301) later this year. For a clinical-stage biotech, securing funding and advancing pipeline assets are critical drivers of value.